2800 Woodlawn Drive, Suite 129
About CardaxCardax is focusing first on developing products utilizing astaxanthin, a naturally occurring compound demonstrated to reduce inflammation, at its source, without the harmful side effects of current anti-inflammatory treatments (e.g., steroids and NSAIDs).
Astaxanthin use is supported by hundreds of peer-reviewed papers published in leading medical research journals. More than 40 human clinical trials supporting the safety and efficacy of astaxanthin have been conducted to date. As the broader scientific community has discovered the health benefits of astaxanthin, awareness and demand for astaxanthin has grown dramatically.
We expect astaxanthin to address underserved multi-billion dollar chronic disease markets, including areas such as osteoarthritis, cognitive decline, metabolic syndrome, dyslipidemia, diabetes, liver disease, and cardiovascular disease.
Cardax has strategic alliances with BASF, related to the proprietary, scalable, and cost-effective manufacture of nature-identical astaxanthin, and Capsugel, related to the proprietary formulation of astaxanthin for increased oral bioavailability. These strategic alliances provide near-term revenue potential from consumer health applications. Cardax may also pursue pharmaceutical applications.
Cardax management and Board have strong operational and technical expertise in healthcare product development and astaxanthin manufacturing and science.
Our patents protect compositions of matter, pharmaceutical compositions, and pharmaceutical uses of astaxanthin and related products in key disease areas.
The safety and efficacy of our product candidates have not been directly evaluated in clinical trials or confirmed by the FDA.
CEO: David G. Watumull
CSO: Gilbert Rishton, PhD
CFO: John Russell
37 articles with Cardax
Financial Results. Operating loss decreased from $906,031 in Q1 2020 to $771,312 in Q1 2021 primarily due to reduced salaries & wages, professional fees, stock based compensation, and selling, general, & administrative expenses.
Cardax, Inc. (OTCQB:CDXI) reported its 2020 results
Financial Results. Operating loss decreased from $1,191,711 in Q3 2019 to $705,760 in Q3 2020, primarily due to a decrease in professional fees, research & development, salaries & wages, and selling, general, & administrative expenses.
Financial Results. Net losses from the same quarter last year decreased 11.7%, from $1,135,420 in Q1 2019 to $1,002,868 in Q1 2020, primarily attributed to a decrease in selling, general, and administration expenses.
CHASE Clinical Trial. On September 23, 2019, the Company announced findings from the pre-specified interim review of its ongoing CHASE clinical trial.
Cardax Releases White Paper on the Potential Role of Astaxanthin in the Treatment of Coronavirus Disease
Cardax seeking strategic collaborations to further develop astaxanthin for COVID-19 (OTCQB:CDXI) today released a white paper outlining the potential role of astaxanthin in the treatment of coronavirus disease and is seeking strategic collaborations to further develop astaxanthin for COVID-19. The
Cardax expects that upon the opening of trading on January 15, 2020, its common stock will trade on the OTCQB on a split-adjusted basis under the current symbol "CDXI" and the new CUSIP number 14141D201.
Cardax, Inc. (OTCQB:CDXI) announced results for the third quarter of 2019.
Cardax, Inc. (OTCQB: CDXI) today announced results from the pre-specified interim review of its ongoing CHASE (Cardiovascular Health Astaxanthin Supplement Evaluation) clinical trial.
Cardax, Inc. filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.
Cardax, Inc. announced that it filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed follow-on public offering of up to $15 million of the Company's common stock and warrants.
Cardax, Inc. (OTCQB:CDXI) announced results for the quarter ended March 31, 2019, in its Quarterly Report on Form 10-Q filed May 15, 2019 with the SEC.
Cardax, Inc. announced results for the year ended December 31, 2018, in its Annual Report on Form 10-K filed today with the SEC.
Cardax, Inc. (OTCQB: CDXI), a life sciences company focused on inflammatory health, today announced that its CEO, David G. Watumull, will present at NobleCon XV—Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida—on January 28th at 11:30 AM Eastern Standard Time.
ZANTHOSYN® #1 AT GNC STORES IN HAWAII FOR PAST 12 MONTHS
Cardax Names Former Amarin Head of Development Paresh N. Soni, MD, PhD, to lead Clinical and Regulatory Strategy
Cardax, Inc. announced that Paresh N. Soni, M.D., Ph.D., the former Senior Vice President and Head of Development for Amarin Corporation, will join Cardax as Chief Clinical and Regulatory Strategist and as a member of the Company's Scientific Advisory Board.
Robust ZanthoSyn® Sales Growth Continues
Cardax, Inc. has launched its Cardiovascular Health Astaxanthin Supplement Evaluation clinical trial targeting cardiovascular inflammatory health.
ZanthoSyn® Sales 4x Higher Than Q2 2017
Company Raises $1.44 Million in Non-Dilutive Financing